Amat-SamaranchVAgut-BusquetEVilarrasaEPuigL.New perspectives on the treatment of hidradenitis suppurativa. Ther Adv Chronic Di. 2021;12:20406223211055920. doi:10.1177/20406223211055920
2.
RingHCYaoYMaulJT, et al. The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study. Br J Dermatol. 2022;187(4):523-530. doi:10.1111/bjd.21673
3.
MarvelJVlahiotisASainski-NguyenAWillsonTKimballA.Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data. BMJ Open. 2019;9(9):e030579. doi:10.1136/bmjopen-2019-030579
4.
GargAGeissbühlerYHouchenE, et al. Disease burden and treatment patterns among US patients with hidradenitis suppurativa: a retrospective cohort study. Am J Clin Dermatol. 2023;24(6):977-990. doi:10.1007/s40257-023-00796-2
5.
DavisSA.Hidradenitis suppurativa management in the United States: an analysis of the National Ambulatory Medical Care Survey and MarketScan Medicaid Databases. Skin Appendage Disord. 2015;1(2):65-73. doi:10.1159/000431037
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
